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Detection of Lipocortin 1 in Human Lung
Lavage Fluid: Lipocortin Degradation As a
Possible Proteolytic Mechanism in the Control
of Inflammatory Mediators and Inflammation
by Susan F. Smith,* Teresa D. Tetley,* Abraham Guz,* and
Roderick J. Flower'
Lipocortins arestructurally related, glucocorticoid-inducible proteinsthatinhibitphopholipase A2
(PLA2), thereby reducing the liberation of arachidonic acid from phospholipids and so limiting the
synthesis ofeicosanoid inflammatory mediators. This study isthe first demonstration ofonelipocor-
tin,lipocortin 1 (Lc 1; 37kDa), inhumanlunglavage supernatants. Inlavagefluidfromhealthyvolunteers,
ahigherpercentage (> 70%)ofthedetectedLc 1 wasinitsnativeform, comparedtothatfrompatients
withabnormallungs. Inpatients' lavagefluids, Lc 1 was morelikelytobepartiallydegraded (34kDa).
In abnormal bronchoalveolar lavage fluid (BALF), the more polymorphonuclear neutrophils
(PMN)/lavage, thelowertheproportion ofLc 1 inthe native (37kDa) form (n = 7 pairs, rs = -0.8214,
p < 0.05). Furthermore, whenBALFcellswereculturedandtheharvestedconditionedmediaincubated
with pure human recombinant Lc 1, degradation ofthe 37 kDa form increased with the percentage of
PMN(n = 10pairs, s = -0.7200after 1 hr; n = 6pairs, rs = -0.9241 after6hr). Theseresults suggest
that factors released from the PMN are responsible for Lc 1 degradation in man. When recombinant
humanLc 1 wasincubatedwithhumanneutrophilelastase, theenzymedegradedLc 1 inadose-dependent
way, suggesting that neutrophil elastase may be one such factor. Since PMNs are ubiquitous at sites
ofinflammation, it is possible that Lc 1 degradation is a permissive mechanism, which ensures that
sufficientinflammation occurstodestroytheprovocativestimulus. However, itisequallypossiblethat,
in some circumstances, the mechanism may be pathological and that the inactivation ofLc 1 leads to
chronic, uncontrolled inflammation.
Introduction
Althoughglucocorticoidshavebeenusedempirically
in the treatment ofinflammatory diseases for40 years,
their mechanisms of action are only now being eluci-
dated. Studies in animals show that the anti-inflam-
matory actions of steroids can be mediated, at least in
part, by afamilyofstructurallyrelatedproteins named
lipocortins 1 through 6. These anti-inflammatory pro-
teins, which aresynthesizedin responsetobothnaturally
occurring and synthetic glucocorticoids (1,2), inhibit
phospholipaseA2(PLA2). Thispreventsthereleasefrom
phospholipid ofarachidonic acid, the common precur-
sorofbothprostaglandinandleukotrieneinflammatory
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mediators. Althoughlipocortinsareproducedbyhuman
cells(3,4)andhumanlipocortingeneshavebeencloned
(5), theexactroleoftheseproteinsinhumanhealthand
disease has yet to be understood.
Asyet, therearenopublisheddataonlipocortininthe
human lung, whether healthy or abnormal, although
lipocortins are present in rat (6) and bovine (7) lungs.
However, there is evidence that human lung cells can
produce steroid-inducible inhibitorsofarachidonicacid
release (8), one of which may be a lipocortin.
Apreviouslypublishedstudyhasshownthatlipocor-
tin 1(Lc 1; 37kDa), themostwidelydistributedandbest
characterized member of the lipocortin family, can be
proteolyzed in vitro by an elastase (probably porcine
pancreatic elastase) (9) to a number of products, with
molecularweightsrangingfrom 18to33kDa. Thefunc-
tional significance of one such fragment (33 kDa) is of
particular interest. Unpublished studies(Flower et al.)
show that in vivo, the 33-kPa form loses the ability to
suppress inflammation; furthermore, it fails to reduce
prostaglandin production and release by peritonealSMITHETAL.
macrophages maintained in vitro, although it appears
toretain90% ofitsPLA2inhibitorycapacity inonecell-
free in vitro assay system (9). In addition, when the
37-kDa protein is proteolyzed, as well as the 33-kDa
form, a3-kDafragmentisliberated fromtheN-terminal
portionoftheparent molecule. Thereissome evidence
thatpeptideswithsequencehomologytothis3-kDafrag-
mentmayhavesome inherentanti-inflammatoryactivi-
ty. Forexample, similarpeptidesareabletoblockformyl-
methionyl-leucyl-phenylalanine (fmlp)-inducedchemo-
taxis in polymorphonuclear neutrophils (PMN) (10),
althoughtheseeffectsoccurathighconcentrationsthat
areprobablynonphysiological. Itthereforeseemslikely
that proteolysis of Lc 1 could have significant patho-
logical effects.
Elastase activities in the human lung are greatly in-
creased by tobacco smoking (11); in addition, elevated
elastase activities have been implicated in the etiology
ofmanypulmonarydiseasesincludingsmoking-related
disorders and some environmentally induced diseases
(12), as well as certain congenital diseases (13).
The first aim of the present study was to establish
whetherornotLc 1 ispresentinthehumanlung. To do
this, lunglavagefluidsfromhealthyhumansubjectsand
frompatientswithvariouslungdiseaseswereanalyzed
forLc 1 andforitsbreakdownproducts. Thesecondaim
ofthe currentinvestigation was to determine whether
or not Lc 1 was degraded (inactivated?) by purified
human neutrophil elastase (NE) and, if so, to find out
if the actions of NE on lipocortin could be reproduced
by exposure of recombinant Lc 1 to media in which
elastase-secretingcells(PMN, andalveolarmacrophages,
AM) had been cultured.
Methods
Materials
Double-lumened, balloon-tippedcatheters(5Fand6F)
wereobtainedfromKimalScientificProductsLtd. (Ux-
bridge, Middx., UK). Centricon units were purchased
from Amicon Ltd. (Stonehouse, Glos., UK). The
PhastSystem electrophoresis apparatus and SDS-
polyacrylamide gradient Phastgels to use on it were
obtained from Pharmacia Ltd. (Milton Keynes, Bucks,
UK), whilethedot-blottingapparatusandnitrocellulose
paper were purchased from Bio-Rad Laboratories Ltd.
(HemelHempstead, Herts., UK). TheChromoscan3gel
scanner was from Joyce-Loebl (Gateshead, Tyne and
Wear, UK). Alltissueculturemediawereobtainedfrom
GibcoLtd.(Paisley, Renfrewshire, UK). Rainbowmolecu-
larweightmarkerswerepurchasedfromAmershamIn-
ternationalplc(Amersham, Bucks, UK). Goatanti-rabbit
IgGconjugatedtohorseradishperoxidase wasobtained
from Sigma Chemical Co. Ltd. (Poole, Dorset, UK).
Neutrophil elastase and itssubstrate, insoluble elastin,
were ordered from Elastin Products Ltd. (Pacific, MO).
Recombinant human Lc 1 andmonospecific antibodies
to the whole molecule were the gifts of Biogen Inc.
(Cambridge, MA). All other chemicals were of AnalaR
gradeandwerepurchasedfromBDHLtd.(Poole,Dorset,
UK).
Subjects
Peripheral lung lavage fluid (PLF;14) was collected
from 6 volunteers (1 male; 6 smokers; median age 26
years, range22-31years)whounderwentbronchoscopy
solelyforresearchpurposes. Informed consentwasob-
tained from all subjects by a clinician who was not in-
volvedinthestudy, andapprovalwasobtainedfromthe
Local Ethical Committee of Charing Cross Hospital.
In addition, PLF was obtained during routine fibre-
opticbronchoscopyof11patients(5male;4nonsmokers,
4 exsmokers, and 3 current smokers; median age 68
yrs, range56-78years). Thefinaldiagnosesonthesepa-
tientswere: fibrosingalveolitis, n = 3; pleuraleffusion,
n = 2; mesothelioma, bronchialcarcinoma, andhemop-
tysisofunknownorigin, each n = 1; no finaldiagnosis,
n = 3.
Centrallunglavagefluid(CLF)(14)wascollectedfrom
4malepatients(1nonsmoker,3currentsmokers;median
age61years, range57-69years); andthefinaldiagnoses:
bronchialcarcinoma, resolvingpneumonia, hemoptysis
ofunknown origin, and no final diagnosis, each n = 1.
An additional 22 patients (14 male; 8 nonsmokers, 4
exsmokers, and 10currentsmokers; medianage56years,
range25-75years)underwentbronchoscopywithbron-
choalveolarlavage(BAL)asaroutinepartoftheirdiag-
nostic work-up. The final diagnoses on these patients
were: normal lung, n = 5; bronchial carcinoma, n = 5;
fibrosingalveolitis, n = 3; sarcoidosis, n = 3; pulmonary
effusion, n = 2; asperillosis, mesothelioma, bronchiec-
tasis, infection, nofinaldiagnosis, eachn = 1. Onesub-
ject had mesothelioma with fibrosing alveolitis, and
thereforetherearen = 23diagnoses. Thesubjectsfound
tohavenormallungswereinvestigatedforunexplained
cough, hemoptysis, or cancerphobia.
Nosubjectincludedinthisstudywasundergoingtreat-
mentwithglucocorticoidsatthetimeofbronchoscopy.
ColiectionandProcessingofLavageFluids
and Preparation for Western Blotting
PLF was collected aspreviously described (14). A 6F
double-lumened, balloon-tipped catheter was passed
throughthebiopsychannelofanunwedgedBF1T Olym-
pusbronchoscopeandwedgedbyinflationoftheballoon
attheleveloftheseventhoreighthgeneration. A20-mL
portionofsterile, warmed0.15mole/Lsalinewasinstilled
throughthesecondlumenandintothelung, belowthe
levelofthewedgedballoon. Itwasaspiratedimmediately
into a sterile trap, and the process was repeated until
100mLsalinehadbeeninstilledintothelungandaspir-
ated into the same trap.
CLFwascollectedaspreviouslydescribed(14). Briefly,
a5Fdouble-lumened,balloon-tippedcatheterwaspass-
ed through the bronchoscope as previously described
andsalinewasinstilledintotheairways-thistimeabove
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theleveloftheballoon, atthefifth orsixthgeneration.
Sterile, warmed0.15mole/Lsaline wasinstilled in4mL
portions and aspirated as previously described, until a
totalof20mLhadbeeninstilled intotheairwayandcol-
lected into a sterile trap.
BAL was carried out as previously described (15).
Warmed, sterile 0.15mole/Lsaline(50 mL) wasinstilled
throughthebiopsychannelofthebronchoscopethat was
wedgedatthethird orfourthgeneration. TheBALfluid
(BALF) was withdrawn immediately into a sterile trap
and the process repeated a further three times.
All PLF, CLF, and 12 of the BALF were processed in
the same way. A sample of 1 to 2 mL was removed for
atotal cellcountusing aNeubauerhemocytometerand
for a differential cell count following Wright-Geimsa
staining. The remainingfluid was filtered through wire
meshandcentrifuged at300gat40C for 15mintopellet
the cells. (Cells from two BALF samples were used for
the culture studies described in the following section).
Lavage supernatants were stored infractions at -20°C
or lower until analysis.
Tbtal protein was measured by the method of Lowry
et al. (16) using bovine serum albumin as a standard.
Samples(2 mL)ofBALFandPLF wereconcentrated ap-
proximately 15-foldand0.2mLsamplesofCLFwere con-
centrated approximately 10-fold by centrifugation in
Centricon units, with molecular weight cut-off 10 kDa,
for 3 hr at 3800g. The final protein concentration was
adjustedto2.5mg/mLwith0.15mole/Lsaline. Samples
wereboiledfor5minwithequalvolumesofsamplebuf-
fer, pH 8, containing Tris-HCl (10 mmole/L), EDTA (1
mmole/L), 5% (w/v)SDS, 10% (v/v)mercaptoethanoland
0.02% (w/v) bromophenol blue. The reduced samples
were stored at 200C prior to Western blotting.
Culture of BALF Cells and Incubation
of Cell Secretions with Recombinant
Human Lipocortin
The cells from 12 BALF samples were cultured as
follows: BALFcellsandsupernatants wereseparated as
previously described. The cells were washed in Hanks'
buffered salt solution (without Ca2+ or Mg2+), then
pelleted by repeat centrifugation at 300g for 15 min at
40C. Thecells werethensuspended inDulbecco'smodi-
fiedEagle's medium orlow-proteinhybridoma medium
andplated outat aconcentrationof 106/mL. Aftera 1-hr
adherence period, the conditioned media and floating
cells were removed and separated by centrifugation at
300g at 40C for 15 min. The media (CM 1) were stored
at -200C. Theadherentcells, mainlyAM, werecultured
in fresh medium for a further 3 hr. Following that, the
conditioned media(CM3)wereremoved, separatedfrom
anyresidualnonadherent cells aspreviouslydescribed,
and stored as previously described.
Fractions of CM 1 and CM 3 were concentrated by
lyophilization or by centrifugation in Centricon units,
(cut-off, 10kDa), at3800gfor3hrat4°C. Purerecombi-
nant Lc 1 (80 Ag/mL) was incubated at 37°C with con-
centratedfractionsofCM 1andCM3fromtheequivalent
of 2 to 20 x 106 elastase-secreting cells (PMN and
AM)/mL for periods of up to 48 hr. Fractions of the in-
cubationmixtureswereremovedatvarioustimepoints,
andthereactionwasterminatedbyboilingfor5minwith
an equal volume ofsample bufferprepared as describ-
ed earlier. Because the amounts of CM varied between
patients, sampleswere nottaken from every subject at
everytimepoint. Collectionswerestaggeredsothatsuf-
ficient samples were available to carry out statistical
analysis on each time point. In order to determine
whether the BALF cells had released any Lc 1 into the
medium, samplesofCM, towhichnoexogenous recom-
binantLc 1 hadbeenadded, werepreparedforWestern
blottingaspreviouslydescribed. Preparedsampleswere
stored at -200C until analysis.
Western Blotting for Lipocortin 1
SDS-polyacrylamidegelelectrophoresis wasperform-
ed on 8 to 25% gradient Phastgels usinga PhastSystem
electrophoresisapparatusaccordingtothemanufactur-
er'sinstructions. A 1-uLfractionoflavagefluid, prepared
as previously described, was applied to each gel and
electrophoresed forapproximately30minat 10mAmps
per gel, maximum voltage, 100 V. Pure recombinant
humanLc 1(80Ig/mL)waspreparedasdescribedabove
and used as a control on every gel. Molecular weight
markers(14.3-200kDa)ofvariouslydyedproteinswere
usedoneachgel. SamplesofrecombinantLc 1(80jAg/mL)
which had been incubated with CM, as previously
described, were electrophoresed in the same way.
Protein bands were transferred from gels to nitro-
cellulose paperbydiffusion underpressure for 18 hrat
room temperature using Tris-glycine-methanol buffer,
pH8(Tris6.25mmole/L + glycine250mmole/L: metha-
nol, 4:1), asacarrier. Completionofproteintransferwas
monitored by observing the colored bands of rainbow
markers.
ThenitrocellulosesheetswereagitatedinTris-buffered
saline(TBS; 0.15mole/LNaCl, 10mmole/LTris-HCl, pH
7), containing 3% (w/v) bovine serum albumin for 1 hr
atroomtemperatureinordertoblockanyremainingpro-
tein binding sites. The sheets were then shaken gently
for 24 hr at 40C (lavage supernatants), or 2 hr at room
temperature (CM/Lc 1 mixtures) with a specific rabbit
anti-recombinanthumanLc 1 antibodydiluted 1 in 1000
with washing buffer [WB; 10 mmole/L Tris-HCl, pH 7,
0.3mole/LNaCl, 0.5% (v/v)Nonidet P-40] containing3%
(w/v)bovine serumalbumin. Theremainingstepswere
performedatroomtemperature. Nonspecificallybound
antibody was removed by exhaustive washing in WB
(without serum albumin). Following this, the blot was
exposedfor 1 to2 hrtogoatanti-rabbitIgG, conjugated
tohorseradishperoxidase diluted 1 in 1000 inWB, con-
taining 3% (w/v) bovine serum albumin. After further
washing in WB followed by TBS, the Lc 1 bands were
visualized by incubation ofthe blots in TBS containing
137SMITHETAL.
diaminobenzidine, 125 ,ig/mL and H202, 0.04 1L/mL.
After a 30- to 60-min incubation, the reaction was ter-
minated by washing the blot in TBS.
Any lavage supernatants that were negative for Lc 1
on Western blotting were immunoblotted using larger
amounts of sample. Briefly, 50-IAL portions of concen-
trated, reduced lavage fluid were applied directly to
nitrocellulose paper using a dot-blotting apparatus ac-
cording tothe manufacturer's instructions. Any Lc 1 in
the sample was then visualized using the antisera and
detection system described previously.
Identification of the Partially Degraded
Lc 1 Band
Duplicate samples of pure recombinant Lc 1 and Lc
1 partially degradedbyincubationwithasample ofCM
1 were electrophoresed as previously described on a
single gel. The gel was then bisected and one set of
samplesWesternblottedasdescribedabove. Thesecond
set ofsamples was blotted using afirst antibody raised
to a peptide with an identical amino-acid sequence to
residues 13 to 26 of human Lc 1. This region of the N-
terminal portion of Lc 1 contains the tyrosine phos-
phorylation site situated at position 21 (5).
The antibody was diluted 1 in 100 with WB contain-
ing3% (w/v)bovineserumalbuminandwasleftbathing
the nitrocellulose sheet for 24 hr. The rest of the blot-
tingprocedurewasaspreviouslydescribed, exceptthat
the horseradish peroxidase-conjugated second anti-
body was diluted 1 in 500, not 1 in 1000, and was left
in contact with the blot for 3 hr.
Blot Scanning: Use and Validation
The Lc bands detected on each individual track of
everyblotwerescannedusingaChromoscan3gelscan-
ner. Eachscanwas0.3 mmwide. Ascanlengthof5mm
was long enough to include the bands of native and
degraded Lc 1. Thescannerwassetinreflectancemode
tomeasureopticaldensityat530nm.Themachinedefm-
edthelimitsofeachbandaccordingtopreprogrammed
parameters, anditcalculatedthetotalandrelativeden-
sitiesofallthebandswithina5mmscan. Itcouldthere-
fore calculate thepercentage ofthetotal Lc 1 detected
in the parent(37 kDa) and proteolyzed (34 kDa) forms.
Thebetween-blotreproducibilitiesoftheabsoluteand
relative densities ofthe 37 and 34 kDaLc 1 bands were
determined by pooling the control data from every
Westernblotandcalculatingthecoefficientofvariance
oftheseparameters. Westernblotswithidenticalsamples
ofpure Lc 1 on every track orwith a different amount
of pure Lc 1 (0-500 ng) on every track were analyzed
inthesamewaytodeterminewithin-blotreproducibili-
tyandtodetermine whetheropticaldensitywaslinear
with respect to the amount of Lc 1 applied to the gel.
Effect of Human Neutrophil Elastase on
Recombinant Human Lc 1
Humanneutrophilelastase(NE)wasactivesitetitrated
usingconstantstakenfromNakajimaetal.(1?). Recom-
binant human Lc 1 was incubated with active (NE) at
37°C in low protein hybridoma medium in molarratios
of0.01 to 1 (NE)to 1 (Lc 1). Fractionsofincubationmix-
tures were removed at intervals up to 48 hr. The reac-
tion was terminated and the samples analyzed by
Western blotting as previously described.
Determination of Elastase Activity (EA)
Elastase activities (EA) of samples of CM and BALF,
andPLFsupernatantsweremeasuredagainstinsoluble
elastin (from bovine ligamentum nuchae) tritiated as
previously described(18). EAwasassayedbythemethod
ofBandaandWerb(18), modifiedaspreviously describ-
ed(15). HumanNEactivesite,titratedasearlierdescrib-
ed, was used as a standard.
Statistics
TheMann-Whitney U testwasusedtocomparelavage
data, whiletheWilcoxonsignedranktestforpaireddata
wasusedtoanalyzetheeffectofCMonLc 1. TheSpear-
man rank correlation coefficient, corrected for tied
values, wascalculatedtoassesstherelationshipbetween
variables. In all analyses, p < 0.05 in a two-tailed test
was taken as statistically significant.
Results
Validation of Scanning Technique
There are two ways of analyzing the degradation of
native Lc 1 (i.e., from 37 to 34kDa)from aWesternblot
scan. The first involves measuringthe reduction in op-
tical density ofthe 37 kDaband. This method requires
a linear relationship between optical density and the
amount of protein in the band. However, the relation-
ship wasnonlinear, particularly at high concentrations
ofLc 1. Furthermore, whenequalamountsofexogenous
Lc 1 were analyzed on each track, the reproducibility
of total optical density measurements was very poor
(lible 1).Thealternativemethodofestimatingdegrada-
tionistomeasurethetotaldensityofthe37kDa(parent)
bandplusthatofthe34kDa(degraded)bandandcalcu-
late the proportion of the total density contributed by
eachband. Usingthismethod, itwasfoundthatthecon-
tributionofthe37kDabandtothetotalopticaldensity
wasvery consistent within and between blots(Thble 1)
and irrespective ofthe total amount of Lc 1 applied to
the gel. Therefore, this measurement has been used
throughout the study.
Comparative Analysis of BALF, PLF,
and CLF
Lipocortin. LC 1 wasdetectedbyWesternblotting
inPLFfromallhealthyvolunteersandin8ofthe 11 PLF
samples from patients. In addition, Lc 1 was detected
in 11 of the 12 BALF samples tested, but it was not
detected in CLF from any subject. However, when
samples of negatively staining lavage fluids were dot-
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lkble 1. Validation of scanning technique.
Coefficient
of
Parameter Condition n x + SDa variance
Total densityb Within blot 7 3144 + 1006 32%
Total density Between blot 45 2240 + 1822 81%
37 kDa, Within blot 14 91 + 3 2%
% of total
37 kDa, Between blot 22 93 ± 5 5%
% of total
aSD, standard deviation.
bTotal density is measured in arbitrary units.
blotted, Lc 1 was then detected in all CLF and PLF and
in all but one of the BALF (data not shown).
The proportions of native (37 kDa) to degraded
(34 kDa) Lc 1 varied considerably between subjects.
However, PLFfromvolunteerscontained atleast70% Lc
1 in the native form (Fig. 1), which was significantly
higher than in PLFfrom patients (lible 2). In contrast,
in BALF, the proportion of 37 to 34 kDa Lc 1 was more
variable and there was no statistically significant dif-
ference inthepercentage ofLc 1 inthenativeformbet-
ween BALF from patients with normal and abnormal
lungs (Thble 2).
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FIGURE 1: Percentage of 37 kDa Lc 1 present in PLF and BALF from
subjectswith normal and abnormallungs. See textand'lible 2 for
statisticallysignificantdifferencesbetween groupsand forcorrela-
tions with other lavage parameters.
Table 2. Recovery of fluid and cells, protein levels, elastase activities and proportions of native Lc 1 in different types
of lavage fluid from subjects with normal and abnormal lungs.
Percent of fluid Cell profile, Tbtal protein, 37 kDa Lc 1,
Group n recovered Cells, x 106 % total mg EA, ng/mg protein % totala
Normal/volunteer PLF 6 33(21-40) 16.3(12.2-21.3) AM 94(81-100) 7.33(5.25-17.55) 27(3-103) 95(73-98)
PMN 4(0-14)
LYM 4(0-7)
Abnormal PLF 11 31(10-68) 4.7(0.1-9.6)b AM 87(58-99) 1.88(0.39-14.15)b 36(0-559) 53(0-100)"
PMN 2(1-25)
LYM 8(0-24)
Normal patient BALF 5 67(31-75)c 27.5(5.4-108.8) AM 91(80-96) 15.88(5.59-47.85) 175(72-395)C 63(0-97)b
PMM 1(0-5)
LYM 4(3-20)
Abnormal BALF 7 39(18-58) 15.3(4.1-580)d AM 55(45-79)e 18.50(7.56-41.70)d 255(38-2860) 32(8-73)
PMN 35(7-56)f
LYM 11(1-15)
Abnormal CLF 4 33(15-45) 0(0-0)g AM ND 0.39(0.02-0.73)g NA ND
PMN ND
LYM ND
a Only samples positive for Lc 1 on Western blotting are included; see Figure 1.
b < Normal PLF.
c > Normal PLF.
d > Abnormal PLF.
e < Abnormal PLF and normal BALF.
f > Abnormal PLF and normal BALF.
g < Abnormal PLF and abnormal BALF.
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When PLF and BALF were compared to each other,
itwasfoundthatPLFfromvolunteershadasignificantly
greaterpercentage ofLc 1 initsnative form thanBALF
from patients with normal lungs (Table 2).
Other Variables. Although there was no statis-
tically significant difference in the percentage of in-
stilledfluidrecovered inPLFfromvolunteerscompared
tothatfrompatients, moreproteinwasrecoveredfrom
volunteer'sPLF(lible2). Morecellswererecoveredfrom
volunteer'sPLF, butthecellprofileswerenotsignificant-
ly different to those from patients. EA/mg protein did
notdifferbetweenthegroupsandneitherdidEA/lavage
(data not shown), despite the significant difference in
protein recoveries.
Therewerenosignificantdifferencesinfluidrecover-
ies, levels oftotal protein, or numbers of BALF cells in
BALF from patients with normal lungs compared to
those with abnormallungs(Thble 2). However, asignifi-
cantly greater proportion of the recovered cells in ab-
normal BALF were PMN (lible 2). EA/mg protein did
not differ between the two sets of BALF.
WhenBALFandPLFfromsubjectswithhealthylungs
were compared, a greater percentage of the instilled
fluid was recovered after BALF, but the total protein,
number, andtypeofcellsrecoveredwasnotsignificant-
ly different between the lavage types. However, the
EA/mg protein was significantly greater in BALF than
in PLF (Thble 2).
Comparison ofBALF and PLFfrom subjects with ab-
normallungsshowednodifference inthepercentageof
instilled fluid recovered. However, protein levels were
higherinBALFthaninPLF. Significantlymorecellswere
recovered in BALF from patients with abnormal lungs,
and the proportion of PMN was greater than in abnor-
mal PLF(Thble 2). EA/mgprotein tended to be greater
in abnormal BALF than in PLF from patients with ab-
normal lungs, but this difference was not statistically
significant.
The percentage ofinstilled fluid recovered afterCLF
was not significantly different to thatafter othertypes
oflavage. Cellswerenotdetected inanyoftheCLF, and
protein levels were significantly lower than in other
lavage types (Table 2). EA was not assayed in these
samples, because of the small volumes of material
available.
CorrelationsofLipocortin with Other Variables.
No statistically significant correlations were found
between the proportion ofLc 1 inthe 37-kDaform and
any variable in PLF from patients or volunteers.
However, in BALF from patients with abnormal lungs,
therewasaninversecorrelationbetweentheproportion
of LC 1 remaining in the native (37 kDa) form and the
numberofPMNinthelavage(n = 7pairs, rs = -0.8214,
p < 0.05). Inaddition, therewasatendencytowardsan
inversecorrelationbetweenthepercentageofnative(37
kDa)Lc 1 andEA/mgprotein(n = 7pairs, rs = -0.7500,
p < 0.10) in BALF from patients with abnormal lungs.
No such relationships were observed in BALFfrom pa-
tients with apparently normal lungs.
Analysis of BALF Cell Secretions in
CM 1 and CM 3 and Their Effect on
Recombinant Lc 1
Under the conditions employed in this study, Lc 1
could not be detected in any sample of CM before the
addition of exogenous recombinant protein.
The cellular equivalents of the CM 1 and CM 3 in-
cubated with recombinant Lc 1 are shown in TAble 3.
PMN were present in CM 1, but not CM 3. EA/105 elas-
tasesecretingcells(ESC) washigherinCM 1 thaninCM
3 (CM 1, 3.3 [0.5-10.0 ng/105 cells]; CM 3, 0.5 [0-9.7
ng/105 cells] median [range] CM 3 < CM 1, p < 0.05).
Therefore, because for any given subject, Lc 1 was in-
cubated with CM 1 and CM 3 derived from equivalent
numbersofelastasesecretingcells, theEA/Lc 1 ratiowas
significantly higher when Lc 1 was incubated with CM
1 thanCM3(lible3). Therewerenosignificantcorrela-
tions between EA and PMN or AM number in CM 1 or
CM 3.
All but two of the CM 1 tested were able to degrade
recombinantLc 1(Thble4), althoughsomesampleswere
muchmoreactiveinthisrespectthanothers. CM3were
generally less active than CM 1 (Fig. 2), although the
groups were not statistically significantly different to
eachother, becauseofthevariabilitybetweendifferent
CM 1 samples in the capacity to degrade Lc 1.
InCM 1thedisappearanceofparent(37kDa)Lc 1 was
positivelycorrelatedtothePMN/Lc 1ratiointhesamples
after 1 and 6 hr incubations, and it tended to be
correlated after 24 hr (Tible 4; 1 hr, n = 10 pairs,
rs = -0.7200,p< 0.05; 6hr, n = 6pairs, rs = -0.9241,
p < 0.05; 24 hr, n = 10 pairs, rs = -0.6398, p < 0.10).
Incontrast, thenumberofAMwasinverselycorrelated
withthedisappearance of37-kDafonnofLc 1 atthe6-hr
timepoint(RTble4; n = 6pairs, rs = -0.6891,p < 0.05).
The disappearance ofparent Lc 1 was not significantly
correlated to EA/Lc 1 ratio in CM 1 at any time point.
There were nostatisticallysignificantlycorrelationsbe-
tweenthe percentage ofnative Lc 1 remainingand any
of the parameters measured in CM 3.
Identification of the Partially Degraded
Form of Lc 1
Although the antibody raised to an amino-acid se-
quence in the N-terminal portion of native Lc 1 cross-
reacted withthe 37-kDaprotein, itfailed to cross-react
withthe34kDaformproducedfollowingincubationfor
3hrwithCM 1 from amixedpopulationofcells(Fig. 3).
Effect ofPure Human NE on Recombinant
Lc 1
IncubationofpureNEandLc 1 atamolarratioof0.1:1
or0.5:1 resultedincomplete degradationofthe37-kDa
proteintothe34-kDaformwithin0.5hr, whileataratio
of 1:1, no lipocortin-derived protein of any molecular
weight could be detected on a Western blotfollowinga
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Ibble3. CellprofilefromwhichCM 1andCM3werederivedand
the effect of these cells on pure recombinant Lc 1.
Ratio/Lc 1 Ratio/Lc 1 Control
CM 1 CM 3 medium
Parameter n > 10 n > 9 n = 2
ESC, x 105a 1.0(0.4-2.0) 1.0(0.4-1.0) 0
AM, x 105 0.7(0.3-10O)b 1.0(0.4-1.0)c 0
PMN, x 105 O.1(0-0.5)d O(0_0)e 0
EA, NEE ngf 3.0(0.5-9.1) 0.3(0-9.7)e 0
Table 4. Time course of Lc 1 degradation by CM 1 and CM 3.
37 kDa, 37 kDa,
% remaining % remaining Control
Time of CM 1 CM 3 medium
incubation, hr n > 6 n = 6 n = 3
0 100 100 100
0.5 94(29-108)g - 102
1.0 91(0-l0l)g 101(55-110) 100
3.0 81(0-102)8 100(0-114) 99
6.0 42(0-97)g 101(0-105) 102
18.0 4(0-105)g 101(0-114) -
24.0 32(0-105)g 97(0-99)g 101
48.0 0(0-105)g 86(0-101) 100
aElastase secreting cells.
b+ ve correlation with 37 kDa remaining in CM 1, 6 hr.
C> CM 1.
d-ve correlation with percentage of percentage of 37 kDa
remaining in CM 1, 1 hr and 6 hr.
e< CM 1.
fneutrophil elastase equivalents.
9< time 0 hr.
See text for rs values. p < 0.05 for all data.
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FIGURE 2: Median percentage of37 kDahuman recombinant Lc 1 re-
maining after different times of incubation with samples of con-
ditioned media (CM 1 and CM 3). CM 1: Percentage of 37 kDa re-
maining < time 0 hr at all incubations times of 1 hr or more, p <
0.05. CM3: Percentageof37 kDaremaining < time 0 hronlyafter
24 hr incubation, p < 0.05.
FIGURE 3: Comparison of Western blots of pure recombinant human
Lc 1 usingantibodiesraisedtothewholeLc 1 molecule(tracksA-D)
orto apeptide consisting ofresidues 13 to 26 from theN-terminal
portion ofthe molecule(tracksE-G). Track D contains molecular
weight markers. The upper horizontal line corresponds to a
molecularweightof37kDa, thelowertoaweightof34kDa.Tracks
CandGcontain untreated purerecombinant human Lc 1. Asmall
proportion is in the 34-kDa form, but only the parent protein is
detected by antibodies to the N-terminal sequence. Tracks A, B,
E, andFcontainrecombinanthumanLc 1 pretreatedfor3hrwith
a sample of CM 1. Tracks A and B show that the majority of the
Lc 1 hasamolecularweightof34kDa. Nobandsarevisible ontracks
E and F, demonstrating that the 34 kDa portion of the molecule
lacks the N-terminal sequence.
0.5 hrincubation(Fig. 4). Decreasing the NE:Lc 1 ratio
to 0.01:1 reduced the rate of loss of lipocortin-derived
protein. However, even at this low ratio, all the protein
was in the 34-kDaform by 0.5 hr. After a 24-hr incuba-
tionwithNEataratioof0.01:1(NE:Lc 1), nolipocortin-
derivedproteinwasdetectableonaWesternblot(Fig.4).
Discussion
Lipocortin 1 was detected in allbut one ofthe lavage
samples analyzed, irrespective of the clinical status or
smokinghistoryofthesubjects. Webelievethistobethe
firstreportofthepresenceofanymemberofthelipocor-
tinfamilyinhumanlunglavagefluid. Inaddition, ithas
beenshownthat, althoughinhealthyvolunteerstheLc
1 was predominantly in its native form, in many ofthe
lavage samples from patients, a high proportion of the
proteinwaspartiallydegraded. Ourinvitrostudiessug-
gestthatthisdegradationcouldbecausedbyoneormore
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FIGURE 4. Western blot of recombinant human Lc 1 following prein-
cubation with NE at different molar ratios. (A) Track G contains
molecularweightmarkers. TracksA-D contain Lc 1 pretreated with
NE at aratioof0.5:1 (NE:Lc 1)for 1, 10, 30, and 60minrespective-
ly. After a 1-min exposure, the majority of the Lc 1 is partially
degraded. By 10 min it is all partially degraded, and by 60 min it
iscompletelyproteolyzed. Tracks E and Fcontain Lc 1 pretreated
with NE at aratioof 1:1 for 10and 30min, respectively. Following
a 10-min exposure, all the Lc 1 is partially degraded, while by 30
min it iscompletely proteolyzed. (C). Track H contains molecular
weight markers. Tracks A-G contain recombinant human Lc 1
pretreated with NE at a molar ratio of 0.01:1 (NE:Lc 1) for 0, 0.5,
1, 3, 6, 24, and 48 hr, respectively. Within 30 min all the Lc 1 has
been proteolyzed to the 34 kDa.
productsofthePMN, whilestudieswithaspecificanti-
bodyindicatethatthispartiallydegradedLc 1 lacksthe
N-terminalportionthatwebelievetobeessentialforfull
anti-inflammatory function in vivo and in cellular
systemsinvitro(Floweretal., unpublishedobservation).
Inpreviousstudies, lipocortinshavebeendetected in
lungtissue fromthe rat(6), from cattle(7) and infeline
tracheal rings (19). The most likely source of the Lc 1
detectedinourlunglavagefluidsistheAM,sincestudies
in the rat (5,20) and on cell lines from various species
(6)showthatmonocytesandmacrophagesarefrequent-
ly rich sources of lipocortins. Lipocortins require Ca2+
to remain attached to the plasma membrane, and thus,
lavage of the lung with a calcium-free solution (NaCI)
mayresultinsome ofthe Lc 1 becomingdetachedfrom
theAMsurfaceandsolubilized inthesupernatantfrac-
tion of the lavage fluid. However, the possibility that
Lc 1 exists in a free form at the epithelial surface can-
not be excluded.
In the current study, amounts of Lc 1 could not be
quantified. Thisisprobablybecausefactorssuchasam-
bient temperature and the activity of conjugated
horseradish peroxidase are difficult to controlbut may
modifythe density ofstaining. In contrast, the relative
proportion of 37 kDa to proteolyzed (34 kDa) Lc 1 was
very reproducible (lible 1) and has, therefore, been
determined.
Takingintoaccountthedegree ofresolutionobtained
withSDS-polyacrylamide electrophoresis, itisprobable
thatthe 34-kDaband observedthroughout the current
study is the same or very similar to the 33-kDa species
generated from human recombinant Lc 1 by Huang et
al. (9). These authors showed theirfragment to be clip-
ped30residuesfromtheN-terminaloftheprecursor(37
kDa)molecule. Inaddition, anearlierstudybythesame
group (6) demonstrated that some of the endogenous
Lc 1 isolatedfromratperitonealextractswasclippedin
the same region. Thus, it seems that both in vivo and
invitro, thisregionofLc 1 isthemostvulnerabletopro-
teolysis. Inthecurrentstudy, ithasbeenshownthatthe
partiallydegradedLc 1 occursinthehumanlung('lble
1) and that NE and possibly otherproducts ofthe PMN
arecapableofcausingsuchdegradation(Thble3). Inad-
dition, thisstudyhasshownthatthe34-kDaformlacks
the N-terminal end of the parent protein since it does
not cross-react with an antibody to this epitope of the
molecule(Fig. 3), increasingtheprobabilitythatwehave
studied the same molecular species as Huang et al. (9).
Althoughtheresultsofcell-freePLA2assays(9)suggest
thatthe clipped form inhibits PLA2, otherauthors con-
sider cell-free systems to be flawed (21). Therefore,
because we believe bioassay to be more relevant to the
situation in man, we are confident that measurement
ofthe ratio of37:34-kDaformsisactually ameasure of
the ratio of functional:nonfunctional Lc 1.
The results ofthe invitro studies(Thble 3) show that
the recombinant Lc 1 was much more actively degrad-
edbyconditionedmediafrommixedpopulationsofcells
containing AM and PMN than that from adherent AM
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alone, suggestingthatthedegradedLc 1 observedinlung
lavage samples may be the result of PMN activity. This
was supported by the observation that degradation of
37 kDa Lc 1 was related to the number of PMN in CM
1 (Thble 3). It is not clear from these data what factor
(orfactors)releasedinto CM1 bythe PMNisresponsible
forthebreakdown ofLc 1. EventhoughpureNE isable
toproteolyze Lc 1 (Fig. 3), norelationship wasobserved
between EA and proteolysis of Lc 1 in our in vitro ex-
periment. There are a number of possible reasons for
this; EA is a measure ofactivity from allelastolytic en-
zymes, some ofwhich maynotdegrade Lc 1, thusinthe
in vitro study, metalloelastase from the AM (22) may
have made a significant contribution to the EA
measured. Furthermore, it is possible that two or more
enzymes actinsequence to degrade Lc 1-forexample,
studieswiththepureproteinshowthatNEfirstdegrades
Lc 1 tothe34-kDaform(Fig. 4). Thismaycause athree-
dimensional change to the lipocortin structure that
makes it more susceptible to attack by other PMN pro-
teases, forexample, cathepsins. Equally, anunidentified
protease could make the initial clip in the parent Lc 1
and NE could perform subsequent degradation.
In view of the animal studies showing macrophages
to be rich in lipocortins (5,20), it is perhaps surprising
thatendogenous Lc 1 was notdetected inmediawhere
AM had been cultured (CM). However, the CM samples
were taken from very small numbers of cells and had
mediafrom alargercellpopulationbeeninvestigated or
the sensitivity ofthe detection system been increased,
Lc 1 might have been detected. Alternatively, because
the tissue culture media contain Ca2+, any Lc 1 pro-
duced by the AM may have remained attached to the
plasma membrane and, thus, would not be detected in
CM. Alternatively, Lc 1 released into the CM may have
already been proteolyzed to small peptides that would
not be detected on a Western blot. A final possibility is
that human AM synthesize a member of the lipocortin
familyotherthanLc 1, whichwouldnotcross-reactwith
our antibody. Further studies will be necessary to dif-
ferentiate between these possibilities.
The results of the immunoblotting experiments in-
dicate that some samples of lavage fluid contain more
Lc 1 than others. While the reasons for differences be-
tween subjects undergoingthe same type oflavage are
unclear, thelowLC 1 levelsinCLF, comparedtoPLFand
BALF, mayreflectthepaucityofAMinthelargeairways
washed during the central lavage procedure. However,
itisalsopossiblethatinsomelavages, particularlyinCLF,
whichcontainrelativelyhighproteaseactivities(14), the
Lc 1 was degraded to small peptides that would not be
detected on a Western blot.
The lavage data(Tble 2) suggest that the proportion
of native to partially degraded Lc 1 reflects both the
health of the subject and the region of the lung sam-
pled. PLFcontainsproportionally less 34 kDa Lcl than
BALF. UnlikeBALF, PLFcontainsnomaterialfromabove
the seventh generation, so it is likely that much of the
34kDaLc 1 inBALFisfromtheairways. Analysisofmore
concentrated samples of CLF or immunoblotting with
theantibodytotheN-terminalepitopewouldclarifythis
point. It is possible that the mucociliary escalator is a
route for clearance, either of nonfunctional lipocortin
orofcells(probablyAM)carryingnonfunctional lipocor-
tin. Alternatively, more degradation of lipocortin may
occur in the upper respiratory tract than in the
periphery, apossibility supportedbyearlierstudiesfrom
this laboratory showing that protease activity per unit
albuminandthenumberofPMN(expressedasapercent-
age ofthe total cell population) are both higher in CLF
thaninPLF(14). Also, itisknownthatphosphorylation
of the tyrosine residue at position 21 of Lc 1 down-
regulatesitsPLA2-inhibitory capacity(23)andthatonce
phosphorylated, it is more susceptible to degradation.
Thus, it is possible that in the upper respiratory tract,
cells are stimulated (for example, to phagocytize and
degrade large inhaled particles deposited in the upper
airways), and that the subsequent downregulation of
lipocortin by phosphorylation results in an increase in
proteolysis of Lc 1.
Summary
Insummary, wehavedemonstratedthatLc 1 ispresent
at the epithelial surface of the human lung, usually in
a variable mixture of native and partially degraded
forms. ThisstudysuggestsaroleforthePMNininactiva-
tion of this protein that may be important in inflam-
matory lung diseases. Further studies to bioassay and
quantify the Lc 1 will be necessary before the physio-
logical significance of these observations can be fully
evaluated.
An influx of PMN during inflammation may be a
mechanismofdownregulatinglipocortinsandwouldper-
mit the inflammatory response necessary to destroy a
provocative stimulus. Removal of the stimulus with
reduced PMN numbers would halt lipocortin degrada-
tion. Equally, itispossiblethatinchronicinflammation,
the inactivation of lipocortin is pathological, perhaps
whenthestimuluscannotbedestroyed, forexample, in
asbestosis or pneumoconiosis. In such situations a
massiveincrease inlipocortinsynthesis, inducedbyhigh
dosesofexogenousglucocorticoids, maythenbetheonly
way of halting the inflammatory process.
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